A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Clinical trial NCT04014205 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04014205
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Part 1：r/r B-cell Malignancies Part 2：B-cell Malignancies

Start date: 2019-11-18
Primary completion: 2026-06-30
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.